Evaluating the cost effectiveness of the addition 2011 RAFIA.pdf (107.38 kB)
Download fileEvaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK
poster
posted on 2020-02-25, 10:35 authored by Rachid Rafia, Diana PapaioannouDiana Papaioannou, Matthew StevensonMatthew Stevenson, J. Rathbone, Helen Buckley WoodsINTRODUCTION
Follicular lymphoma (FL), a clinical subtype of Non-Hodgkin’s lymphoma (NHL) , develops
slowly and often without symptoms for many years. In 2008, the incidence of FL in England
and Wales was 3.4 per 100,000 persons. Over 70% of FLs are diagnosed in persons aged
over 60 years, and 85-90% present with advanced disease, which is defined as lymph nodes
on both sides of the diaphragm being involved (stage III) or disease is disseminated with one
or more extra-lymphatic organs involved (stage IV). Advanced FL is not curable, thus the aim
of disease management is to both increase patient life expectancy and to increase patient
health-related quality of life. The objective of this study is to assess, from a UK NHS
perspective, the cost-effectiveness of the addition of rituximab (R) to selected
chemotherapies: CVP (cyclophosphamide, vincristine and prednisolone); CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisolone) and MCP (mitoxantrone,
chlorambucil and prednisolone) in the first-line treatment of follicular lymphoma.
History
Ethics
There is no personal data or any that requires ethical approvalPolicy
The data complies with the institution and funders' policies on access and sharingSharing and access restrictions
The data can be shared openlyData description
- The file formats are open or commonly used
Methodology, headings and units
- Headings and units are explained in the files